View Rule
| View EO 12866 Meetings | Printer-Friendly Version Download RIN Data in XML |
| HHS/FDA | RIN: 0910-AF95 | Publication ID: Spring 2011 |
| Title: Over-the-Counter (OTC) Drug Review-Certain Category II Active Ingredients | |
| Abstract: The Food and Drug Administration (FDA) is proposing that certain ingredients in over-the-counter (OTC) drug products are not generally recognized as safe and effective or are misbranded. FDA issued this proposed rule because we did not receive any data and information on these ingredients in response to our request on December 31, 2003 (68 FR 75585). This rule will finalize the 2008 proposed rule. | |
| Agency: Department of Health and Human Services(HHS) | Priority: Routine and Frequent |
| RIN Status: Previously published in the Unified Agenda | Agenda Stage of Rulemaking: Completed Actions |
| Major: No | Unfunded Mandates: No |
| CFR Citation: 21 CFR 201 21 CFR 310 21 CFR 330 to 358 | |
| Legal Authority: 21 USC 321p 21 USC 331 21 USC 351 to 353 21 USC 355 21 USC 360 21 USC 371 | |
|
Legal Deadline:
None |
||||||||||||
Timetable:
|
| Regulatory Flexibility Analysis Required: Yes | Government Levels Affected: Local, State |
| Small Entities Affected: Businesses | Federalism: Yes |
| Included in the Regulatory Plan: No | |
| RIN Data Printed in the FR: Yes | |
|
Agency Contact: David Eng Regulatory Project Manager Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, WO 22, Room 5487, 10903 New Hampshire Avenue, Silver Spring, MD 20993 Phone:301 796-2773 Fax:301 796-9899 Email: david.eng@fda.hhs.gov |
|
An official website of the United States government



